IIPM: Indian pharmaceutical players have been among the frontrunners that have moved in for the kill

Indian pharmaceutical players have been among the frontrunners that have moved in for the kill, more so in the post-liberalisation era. They are not just reveling in the plethora of opportunities that have opened up, thanks largely to a number of patents expiring. Indian companies, irrespective of their size, are taking up the cudgels in every sphere of the gargantuan pharma

space, and they even have a war chest ready to enable them to gobble-up First World companies, as and when required. However, on the other hand, the Indian players have also learned (the hard way) how tough the generic business can be. This is a space that has seen murderous price wars (particularly in the US), despite the fact that China, the undisputed master of the pricing game, doesn’t account for much in the pharma sweepstakes. Even though they are enjoying their day in the sun, these firms still lack the financial and R&D muscle of the beleaguered pharma giants. Will Indian firms ever be able to metamorphose into giant killers? We take a closer look…

For Complete IIPM Article, Click here

Source: IIPM Editorial, 2006

An IIPM and Management Guru Prof. Arindam Chaudhuri's Initiative